HRD: Homologous Recombination Deficiency
HRD Score to help assess tumor HRD status.
HRD Pro Testing uses NGS to assess genomic instability and generate a score that can be discussed with the oncology team.
What Does the Test Assess?
HRD Score
Assesses the level of genomic instability in the tumor.
BRCA1 & BRCA2 gene status*
BRCA1 and BRCA2 status can be discussed with the oncology team alongside other clinical information.
Treatment Response
HRD results can inform discussion of PARP-inhibitor therapy; they do not guarantee treatment response.
*for HRD PRO Testing service
Which Cases May Require Testing?
Patients with epithelial ovarian cancer
Triple-negative breast cancer
Castration-resistant prostate cancer
Pancreatic cancer
When Is Testing Performed?
After surgery
After chemotherapy and/or radiotherapy
For routine cancer monitoring
How Are Samples Tested?
Tissue and Whole-Blood Samples
Tissue and whole-blood samples are analyzed using Next Generation Sequencing (NGS). The HRD Score is an input for discussion with the oncology team, not a guarantee of treatment response.
Understand HRD Status to Support More Targeted Treatment.
HRD Testing Specifications
Next Generation Sequencing
Tissue and whole blood
17 working days